Impact of dose reductions on efficacy outcome in heart transplant patients receiving enteric-coated mycophenolate sodium or mycophenolate mofetil at 12 months post-transplantation.

摘要: Mycophenolic acid (MPA) dose reduction is associated with increased risk of rejection and graft loss in renal transplantation. This analysis investigated the impact MPA changes enteric-coated mycophenolate sodium (EC-MPS) or mofetil (MMF) de novo heart transplant recipients. In a 12-month, single-blind trial, 154 patients (EC-MPS, 78; MMF, 76) were randomized to either EC-MPS (1080 mg bid) MMF (1500 combination cyclosporine steroids. The primary efficacy variable was incidence treatment failure, comprising composite biopsy-proven (BPAR) treated acute rejection, death. Significantly fewer receiving required > =2 reductions than on (26.9% vs. 42.1% patients, p = 0.048). Accordingly, average daily as percentage recommended significantly higher for (88.4% 79.0%, 0.016). Among requiring =1 reduction, BPAR grade =3A lower compared (23.4% 44.0%, 0.032). These data suggest that EC-MPS-treated are less likely require multiple those which may be =3A.